29 unchanged sentences
(the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2025, based on the COSO criteria.
−Removed: We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of Inspire Medical Systems, Inc.
−Removed: as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive income (loss), stockholders' equity and cash flows for each of the three years in the period ended December 31, 2024, and the related notes and our report dated February 10, 2025 expressed an unqualified opinion thereon.
+Added: We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2025 and 2024, the related consolidated statements of operations and comprehensive income (loss), stockholders' equity and cash flows for each of the three years in the period ended December 31, 2025, and the related notes and our report dated February 13, 2026 expressed an unqualified opinion thereon.
Basis for Opinion
19 unchanged sentences
(b) Adoption or Termination of Trading Arrangements by Directors and Executive Officers
−Removed: Name Title Action Rule 10b5-1
−Removed: Adoption/Termination Date Aggregate Number of Shares of Common Stock to be Sold Expiration Date
−Removed: Shawn T McCormick Director Terminate November 1, 2024 1,050 May 2, 2025
−Removed: Shawn T McCormick Director Adopt November 13, 2024 8,600 August 15, 2025
−Removed: Buchholz Chief Financial Officer Adopt November 13, 2024 15,000 November 28, 2025
−Removed: Randall Ban EVP Patient Access and Therapy Development Adopt November 13, 2024 25,000 August 15, 2025
−Removed: Bryan Phillips General Counsel Adopt November 27, 2024 6,152 (1)
−Removed: September 30, 2025
−Removed: (1) This number includes shares of our common stock issuable pursuant to performance stock units (“PSU”) that may vest during the term of the 10b5-1 plan, subject to the achievement of certain performance conditions as set forth in the applicable PSU agreement.
−Removed: The actual number of PSUs that vest following the end of the applicable performance period, if any, and therefore the resulting shares of our common stock available for sale under the plan will depend on the attainment of the performance metrics.
−Removed: Also, shares of our common stock issuable pursuant to vested PSUs will be subject to tax withholding obligations that may reduce the net shares actually issued and, therefore, available for sale under the applicable plan;
−Removed: however, the maximum aggregate gross number of shares of our common stock included in the applicable plan is reported in this table without reduction for such future tax obligations and assuming maximum achievement of the performance conditions under the PSUs.
−Removed: There were no other "Rule 10b5-1 trading arrangements" or "non-Rule 10b5-1 trading arrangements," as each term is defined in Item 408(a) of Regulation S-K, adopted , modified or terminated by the Company’s directors or "officers" (as defined in Rule 16a-1(f) of the Exchange Act) during the quarter ended December 31, 2024.
+Added: There were no "Rule 10b5-1 trading arrangements" or "non-Rule 10b5-1 trading arrangements," as each term is defined in Item 408(a) of Regulation S-K, adopted , modified or terminated by the Company’s directors or "officers" (as defined in Rule 16a-1(f) of the Exchange Act) during the quarter ended December 31, 2025.
Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.
87 unchanged sentences
10-K 001-38468 10.14 2/15/2022
+Added: 10.13† Amended Form of Stock Option Award Agreement under Inspire Medical Systems, Inc.
+Added: 2018 Incentive Award Plan for awards granted on or after December 9, 2024
+Added: 10-Q 001-38468 10.2 5/5/2025
+Added: 10.14† Amended Form of Restricted Stock Unit Award Agreement under Inspire Medical Systems, Inc.
+Added: 2018 Incentive Award Plan for awards granted on or after December 9, 2024
+Added: 10-Q 001-38468 10.3 5/5/2025
+Added: 10.15† Amended Form of Performance Stock Unit Award Agreement under Inspire Medical Systems, Inc.
+Added: 2018 Incentive Award Plan for awards granted on or after December 9, 2024
+Added: 10-Q 001-38468 10.4 5/5/2025
10.16† Inspire Medical Systems, Inc.
15 unchanged sentences
Employment Agreement between the Company and Jason Kelly
−Removed: 10.20† Form of Indemnification Agreement between Inspire Medical Systems, Inc.
−Removed: and its directors and officers
−Removed: S-1 333-224176 10.23 4/6/2018
+Added: 10-K 001-38468 10.19 2/10/2025
+Added: 10.23† Transition and Separation Agreement by and between Inspire Medical Systems, Inc.
+Added: and Richard J.
+Added: 001-38468 10.1 8/26/2025
+Added: 10.24† Amendment to Transition and Separation Agreement by and between Inspire Medical Systems, Inc.
+Added: and Richard Buchholz
+Added: 10.25† Employment Agreement between the Company and Matthew J.
10.26† Inspire Medical Systems, Inc.
1 unchanged sentence
10-Q 001-38468 10.1 5/5/2025
+Added: 10.27† Form of Indemnification Agreement between Inspire Medical Systems, Inc.
+Added: and its directors and officers
+Added: S-1 333-224176 10.23 4/6/2018
19.1 Inspire Medical Systems, Inc.
Insider Trading Policy
+Added: 10-K 001-38468 19.1 2/10/2025
21.1 Subsidiaries of Inspire Medical Systems, Inc.
1 unchanged sentence
31.1 Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
+Added: Number Description Form File No.
+Added: Exhibit Filing
31.2 Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
8 unchanged sentences
101.SCH Inline XBRL Taxonomy Extension Schema Document *
−Removed: Number Description Form File No.
−Removed: Exhibit Filing
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document *
16 unchanged sentences
/s/ TIMOTHY P.
−Removed: President and Chief Executive Officer
+Added: President, Chief Executive Officer, and Chairperson
(principal executive officer)
3 unchanged sentences
HERBERT Chief Executive Officer (principal executive officer), President and Chair of the Board of Directors
−Removed: /s/ RICHARD BUCHHOLZ Chief Financial Officer (principal financial and accounting officer)
+Added: /s/ RICHARD BUCHHOLZ Interim Chief Financial Officer (principal financial and accounting officer)
Richard Buchholz
11 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.